🧾 What This Document Is

This is an 8-K filing, which is a current report companies use to announce major events to shareholders. This specific filing includes the full-year 2025 financial results and a detailed business update. Think of it as a "state of the union" for investors, showing where the company has been, where it is now, and where it's heading.

🏢 What The Company Does

👉 In simple terms, RenovoRx is a medical company with two main focuses. First, they sell a cleared medical device called RenovoCath®, which doctors use to deliver cancer drugs directly to a tumor's blood supply. Second, they are running a major clinical trial testing a drug-device combination (their device plus the chemotherapy drug gemcitabine) for treating pancreatic cancer. They aim to be a leader in targeted cancer therapy.

💰 Financial Highlights

Let's look at the key numbers for 2025.

Revenue: The company made $1.1 million from selling RenovoCath. This is a big jump from just $43,000 in 2024, marking their first full year of commercial sales.
Cash Position: They ended 2025 with $7.0 million in cash. However, a key event happened after the year ended: they raised $10 million in a private placement (netting $9.2 million), giving them a total of $13 million in cash as of March 2026.
Net Loss: The company lost $11.2 million in 2025, up from an $8.8 million loss in 2024. This is typical for a growing biotech company investing heavily in sales and research.
Per Share Loss: The net loss was $0.32 per share.

👉 Why it matters: The story here is growth and investment. Revenue is scaling from a very low base, but costs are rising faster as they build a sales team and run a costly clinical trial. The recent $13 million cash pile is crucial—it gives them the fuel to reach their next milestones without running out of money.

🚀 Key Moves

The company made several important strategic moves in late 2025 and early 2026.

Built a Commercial Team: They established their sales and marketing infrastructure in Q4 2025. This is the engine they hope will drive RenovoCath sales growth.
Strengthened Leadership: They hired a new CFO, Mark Voll, in February 2026, bringing in 30+ years of financial experience to guide their growth phase.
Formed an Advisory Board: They created a Medical Advisory Board (MAB) with six leading cancer doctors to guide their therapy platform's development.
Raised Critical Capital: The $10 million private placement in March 2026 was a major success, oversubscribed and involving new institutional investors. This de-risks their near-term financial survival.

📦 Financial Position

Looking at their balance sheet gives a snapshot of health.

Assets vs. Liabilities: As of Dec 31, 2025, total assets were $8.1 million and total liabilities were $2.7 million, resulting in stockholders' equity of $5.4 million. After the $9.2 million cash injection in March, their equity and cash position improved significantly.
What it signals: The company is still in an early, cash-burning phase. The recent financing was critical to bolster the balance sheet, providing the runway to hit clinical and commercial targets over the next 1.5-2 years.

💸 Cash Flow Story

While the full cash flow statement isn't detailed, we can infer the story from the data.

Cash was used for: Funding operations, primarily the $6.3 million in R&D (mostly for the TIGeR-PaC trial) and $7.0 million in SG&A expenses (to build the commercial team and run the company).
Cash came from: The aforementioned $9.2 million net financing. The $1.1 million in revenue helped, but didn't come close to covering the $13.3 million in total operating expenses.
What it reveals: This is a classic growth-stage cash burn profile. The company is investing heavily today to build a commercial business and generate clinical data, hoping for significant revenue tomorrow.

🔮 What's Next

The company has very clear, near-term milestones.

Commercial Growth: The focus for 2026 is to scale RenovoCath sales, aiming to convert the 17 clinical trial sites into paying commercial customers in the second half of 2026.
Clinical Trial Completion: The pivotal Phase III TIGeR-PaC trial is the main event. They aim to complete enrollment by mid-2026 (requiring 114 patients; 104 are randomized as of March 24). Final data is expected in 2027.
Path to Profitability: Management explicitly stated they are driving towards breakeven operations and positive trial data. The $13 million cash is intended to get them there.

⚖️ Big Picture

👍 Strengths:

A commercial product (RenovoCath) generating real, growing revenue.
A Phase III trial on a clear timeline for a large cancer indication (pancreatic cancer).
A newly fortified balance sheet with $13M to execute their plan.
Strategic moves: a seasoned CFO, a sales team, and an expert advisory board.

⚠️ Risks:

They are still losing money and are not yet profitable.
The pivotal TIGeR-PaC trial must succeed for the major drug-device combo therapy to have value. Any negative data could be devastating.
Commercial adoption, while promising, is still early. They need to significantly scale sales to justify their valuation.

🧠 The Analogy

Imagine RenovoRx is like a specialized construction company that just finished building its first house (RenovoCath revenue) and now has the blueprints and funding to build a whole neighborhood (the clinical trial and commercial scale-up). The next two years are about proving they can build the big, landmark project (TIGeR-PaC trial results) that will make them famous and bring in major contracts.

📇 Key Contacts & People

Shaun Bagai, Chief Executive Officer
Mark Voll, Chief Financial Officer (appointed Feb 2026)
Medical Advisory Board Members: Nadine Abi-Jaoudeh, MD (UCI Health); Mustafa Al-Roubaie, MD (Moffitt Cancer Center); Khashayar Farsad, MD, PhD (Oregon Health & Science University); Ripal Gandhi, MD (Baptist Health South Florida); Paula Marie Novelli, MD (UPMC); Jonathan Kessler, MD (City of Hope)
Investor Relations Contact: KCSA Strategic Communications - Valter Pinto or Jack Perkins | T: 212-896-1254 | [email protected]

🧩 Final Takeaway

RenovoRx is in a critical transition phase, moving from a development-stage company to a commercial one. They have successfully launched their device, raised crucial funding, and are on the final stretch of their make-or-break clinical trial. The next 18 months will determine if their targeted cancer therapy approach is a commercial and clinical success.

RenovoRx, Inc. — 8-K Filing